Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

This article explores how challenges such as sequence optimization, immune activation and off-target effects are being addressed to enhance the safety, durability and efficacy of RNA therapeutics.

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal ...

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Wave Life Sciences Ltd. tops our list for being one of the most promising stocks. TheFly reported on ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

Sweetpotato farmers may soon have higher yields of the root crop after University of the Philippines Los Baños (UPLB) ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

B.C. is reviewing whether to fund an expensive drug for patients who have a genetic condition that causes dangerously high ...